Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Vicadrostat in Healthy Males
NCT03100916Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of vicadrostat in chronic kidney disease (CKD) and hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of subjects with drug-related Adverse Events at Day 30. Started May 2017; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NCT03100916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100916.